Sign in or create an account to add this stock to your watchlist.
About Five Prime Therapeutics (NASDAQ:FPRX)
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FPRX
CUSIPN/A
Phone415-365-5600
Debt
Debt-to-Equity RatioN/A
Current Ratio9.79
Quick Ratio9.79
Price-To-Earnings
Trailing P/E Ratio-3.42
Forward P/E Ratio-3.73
P/E GrowthN/A
Sales & Book Value
Annual Sales$39.51 million
Price / Sales16.41
Cash FlowN/A
Price / CashN/A
Book Value$10.29 per share
Price / Book1.79
Profitability
EPS (Most Recent Fiscal Year)($5.38)
Net Income$-150,220,000.00
Net Margins-221.74%
Return on Equity-44.36%
Return on Assets-36.14%
Miscellaneous
Employees216
Outstanding Shares35,210,000
Five Prime Therapeutics (NASDAQ:FPRX) Frequently Asked Questions
What is Five Prime Therapeutics' stock symbol?
Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."
How were Five Prime Therapeutics' earnings last quarter?
Five Prime Therapeutics Inc (NASDAQ:FPRX) posted its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.55) by $0.08. The biotechnology company had revenue of $32.49 million for the quarter, compared to the consensus estimate of $37.50 million. Five Prime Therapeutics had a negative return on equity of 44.36% and a negative net margin of 221.74%. View Five Prime Therapeutics' Earnings History.
What price target have analysts set for FPRX?
6 brokers have issued 12-month price objectives for Five Prime Therapeutics' shares. Their predictions range from $17.00 to $60.00. On average, they expect Five Prime Therapeutics' stock price to reach $37.3333 in the next twelve months. View Analyst Ratings for Five Prime Therapeutics.
Who are some of Five Prime Therapeutics' key competitors?
Some companies that are related to Five Prime Therapeutics include Tesaro (TSRO), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Emergent Biosolutions (EBS), Horizon Pharma (HZNP), Evotec A.G. (EVTCY), Global Blood Therapeutics (GBT), The Medicines (MDCO), Arena Pharmaceuticals (ARNA), Heron Therapeutics (HRTX), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Intercept Pharmaceuticals (ICPT) and Corcept Therapeutics (CORT).
Who are Five Prime Therapeutics' key executives?
Five Prime Therapeutics' management team includes the folowing people:
- Lewis T. Williams M.D. Ph.D., Executive Chairman of the Board (Age 67)
- Aron Marc Knickerbocker MBA, President, Chief Executive Officer, Chief Operating Officer, Director (Age 47)
- Marc L. Belsky, Chief Financial Officer, Senior Vice President (Age 61)
- Kevin Baker Ph.D., Senior Vice President, Development Sciences (Age 56)
- Helen Louise Collins M.D., Senior Vice President and Chief Medical Officer (Age 54)
- Francis Willard Sarena J.D., Chief Strategy Officer and Secretary (Age 46)
- Mark D. McDade, Lead Independent Director (Age 61)
- Garry Nicholson, Director
- Franklin M. Berger, Independent Director (Age 67)
- Fred E. Cohen Ph.D. M.D., Independent Director (Age 60)
Has Five Prime Therapeutics been receiving favorable news coverage?
Media headlines about FPRX stock have been trending somewhat positive on Thursday, according to Accern Sentiment. Accern identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Five Prime Therapeutics earned a media sentiment score of 0.21 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 47.67 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Five Prime Therapeutics' major shareholders?
Five Prime Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.56%), Victory Capital Management Inc. (3.04%), Dimensional Fund Advisors LP (2.96%), BB Biotech AG (2.78%), Rock Springs Capital Management LP (1.66%) and Northern Trust Corp (1.05%). Company insiders that own Five Prime Therapeutics stock include Francis Willard Sarena, Lewis T Williams, Peder Jensen and William R Ringo. View Institutional Ownership Trends for Five Prime Therapeutics.
Which major investors are selling Five Prime Therapeutics stock?
Which major investors are buying Five Prime Therapeutics stock?
FPRX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Rock Springs Capital Management LP, BB Biotech AG, DekaBank Deutsche Girozentrale, Victory Capital Management Inc., Millennium Management LLC, UBS Group AG and State of Wisconsin Investment Board. View Insider Buying and Selling for Five Prime Therapeutics.
How do I buy shares of Five Prime Therapeutics?
Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Five Prime Therapeutics' stock price today?
One share of FPRX stock can currently be purchased for approximately $18.41.
How big of a company is Five Prime Therapeutics?
Five Prime Therapeutics has a market capitalization of $685.53 million and generates $39.51 million in revenue each year. The biotechnology company earns $-150,220,000.00 in net income (profit) each year or ($5.38) on an earnings per share basis. Five Prime Therapeutics employs 216 workers across the globe.
How can I contact Five Prime Therapeutics?
Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600.
MarketBeat Community Rating for Five Prime Therapeutics (FPRX)
MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote "Outperform" if you believe FPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Five Prime Therapeutics (NASDAQ:FPRX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Five Prime Therapeutics in the last 12 months. Their average twelve-month price target is $37.3333, suggesting that the stock has a possible upside of 102.79%. The high price target for FPRX is $60.00 and the low price target for FPRX is $17.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $37.3333 | $46.75 | $67.75 | $67.75 |
| Price Target Upside: | 102.79% upside | 151.61% upside | 54.82% upside | 54.82% upside |
Five Prime Therapeutics (NASDAQ:FPRX) Consensus Price Target History
Five Prime Therapeutics (NASDAQ:FPRX) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Five Prime Therapeutics (NASDAQ:FPRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Five Prime Therapeutics (NASDAQ FPRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.40%
Institutional Ownership Percentage: 91.94%
Five Prime Therapeutics (NASDAQ FPRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/1/2017 | William R Ringo | Director | Sell | 600 | $45.33 | $27,198.00 | 600 |  |
| 10/2/2017 | William R Ringo | Director | Sell | 1,800 | $40.26 | $72,468.00 | 1,200 | |
| 9/28/2017 | William R Ringo | Director | Sell | 2,000 | $38.00 | $76,000.00 | 2,000 | |
| 3/1/2017 | William R Ringo | Director | Sell | 500 | $46.73 | $23,365.00 | 500 | |
| 2/1/2017 | William R Ringo | Director | Sell | 500 | $46.17 | $23,085.00 | 500 | |
| 1/18/2017 | Francis Willard Sarena | Insider | Sell | 3,636 | $47.39 | $172,310.04 | 82,460 | |
| 1/3/2017 | William R Ringo | Director | Sell | 500 | $51.07 | $25,535.00 | 500 | |
| 12/23/2016 | Lewis T Williams | CEO | Sell | 30,000 | $50.50 | $1,515,000.00 | 434,047 | |
| 12/1/2016 | William R Ringo | Director | Sell | 500 | $57.72 | $28,860.00 | 500 | |
| 11/28/2016 | Francis Willard Sarena | Insider | Sell | 1,710 | $60.14 | $102,839.40 | 82,976 | |
| 11/25/2016 | Francis Willard Sarena | Insider | Sell | 34,654 | $60.38 | $2,092,408.52 | 94,731 | |
| 11/9/2016 | Peder Jensen | Director | Sell | 8,130 | $55.30 | $449,589.00 | 4,065 | |
| 11/1/2016 | William R Ringo | Director | Sell | 500 | $48.67 | $24,335.00 | 500 | |
| 10/3/2016 | William R Ringo | Director | Sell | 500 | $52.00 | $26,000.00 | 500 | |
| 9/1/2016 | William R Ringo | Director | Sell | 500 | $44.20 | $22,100.00 | 500 | |
| 8/1/2016 | William R Ringo | Director | Sell | 500 | $50.77 | $25,385.00 | 500 | |
| 7/27/2016 | Peder Jensen | Director | Sell | 12,195 | $49.50 | $603,652.50 | 12,195 | |
| 4/22/2016 | Franklin M Berger | Director | Buy | 5,000 | $49.47 | $247,350.00 | 81,980 | |
| 4/22/2016 | Marc Belsky | CFO | Sell | 34,102 | $50.00 | $1,705,100.00 | 88,410 | |
| 4/21/2016 | Lewis T Williams | CEO | Sell | 48,671 | $48.05 | $2,338,641.55 | 341,078 | |
| 4/19/2016 | Franklin M Berger | Director | Buy | 6,090 | $47.06 | $286,595.40 | 77,890 | |
| 4/15/2016 | Lewis T Williams | CEO | Sell | 1,405 | $48.00 | $67,440.00 | 341,933 | |
| 4/14/2016 | Lewis T Williams | CEO | Sell | 2,725 | $48.00 | $130,800.00 | 343,253 | |
| 4/6/2016 | Lewis T Williams | CEO | Sell | 52,801 | $43.09 | $2,275,195.09 | 366,477 | |
| 4/6/2016 | Marc Belsky | CFO | Sell | 20,814 | $45.04 | $937,462.56 | 81,278 | |
| 3/30/2016 | Francis Willard Sarena | EVP | Sell | 10,000 | $40.01 | $400,100.00 | 88,284 | |
| 3/30/2016 | Lewis T Williams | CEO | Sell | 23,259 | $40.02 | $930,825.18 | 349,743 | |
| 3/30/2016 | Marc Belsky | CFO | Sell | 13,876 | $40.01 | $555,178.76 | 85,751 | |
| 3/2/2016 | Lewis T Williams | CEO | Sell | 23,259 | $36.01 | $837,556.59 | 363,611 | |
| 2/4/2016 | Lewis T. Williams | CEO | Sell | 71,229 | $33.35 | $2,375,487.15 | 340,352 | |
| 1/27/2016 | Francis Willard Sarena | EVP | Sell | 30,000 | $35.22 | $1,056,600.00 | | |
| 10/15/2015 | Adage Capital Partners Gp Llc | Major Shareholder | Sell | 125,000 | $27.75 | $3,468,750.00 | | |
| 10/15/2015 | Lewis T. Williams | CEO | Sell | 72,352 | $27.24 | $1,970,868.48 | 294,593 | |
| 9/21/2015 | Lewis T Williams | CEO | Sell | 2,648 | $22.06 | $58,414.88 | 366,945 | |
| 6/22/2015 | Lewis T Williams | CEO | Sell | 75,000 | $24.67 | $1,850,250.00 | | |
| 1/28/2015 | Franklin M Berger | Director | Buy | 25,000 | $27.03 | $675,750.00 | | |
| 1/15/2015 | Franklin M Berger | Director | Buy | 10,049 | $26.17 | $262,982.33 | | |
| 11/28/2014 | Franklin M Berger | Director | Buy | 1,951 | $21.04 | $41,049.04 | | |
| 11/4/2014 | Lewis T Williams | CEO | Sell | 32,603 | $13.08 | $426,447.24 | | |
| 10/30/2014 | Lewis T Williams | CEO | Sell | 17,397 | $13.13 | $228,422.61 | | |
| 9/23/2013 | Brian G Atwood | Director | Buy | 76,923 | $13.00 | $999,999.00 | | |
(Data available from 1/1/2013 forward)
Five Prime Therapeutics (NASDAQ FPRX) News Headlines
| Source: |
|
Five Prime Therapeutics (NASDAQ:FPRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Five Prime Therapeutics (NASDAQ:FPRX) Income Statement, Balance Sheet and Cash Flow Statement
Five Prime Therapeutics (NASDAQ FPRX) Stock Chart for Thursday, May, 24, 2018
Loading chart…
